PRODUCTS

ALT-711 (thiazolium chloride), 15 mg/ml x 30ml
September 18, 2017
Fragment (176-191) 5mg/mlx2ml 3-VIALS
September 19, 2017

CJC 1295 W / DAC 2mg / 2 ml

$59.99

CJC-1295 is a tetrasubstituted 30-amino acid peptide hormone, primarily functioning as a growth hormone releasing hormone (GHRH) analog.

Description

CJC-1295, also known as DAC:GRF (short for drug affinity complex:growth hormone-releasing factor), is a synthetic analogue of growth hormone-releasing hormone (GHRH) (also known as growth hormone-releasing factor (GRF)) and a growth hormone secretagogue (GHS) which was developed by ConjuChem Biotechnologies.[1][2][3] It is a modified form of GHRH (1-29) with improved pharmacokinetics, especially in regard to half-life.[1][2][3][4]

CJC-1295 markedly increases plasma growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels in both animals and humans.[1][2][3][5] With a single injection, in human subjects, CJC-1295 increases plasma GH levels by 2- to 10-fold for 6 days or longer and plasma IGF-1 levels by 1.5- to 3-fold for 9 to 11 days.[3] The drug has an estimated half-life of about 6 to 8 days in humans.[3] With multiple doses of CJC-1295, IGF-1 levels were found to remain elevated in humans for up to 28 days.[3]

CJC-1295 has been shown to extend the half-life and bioavailability of growth-hormone-releasing hormone 1-29 and stimulate insulin-like growth factor 1 secretion. It increases the half-life of acting agents by bioconjugation.[6]

CJC-1295 was under investigation for the treatment of lipodystrophy and growth hormone deficiency and reached phase II clinical trials but was discontinued upon the death of one of the trial subjects.[7][8] The attending physician of the trial believed that the most likely explanation for the incident was that the patient had asymptomatic coronary artery disease with plaque rupture and occlusion, and that the occurrence was unrelated to treatment with CJC-1295.[8] In any case, research was terminated nonetheless as a precaution.[8] CJC-1295 has found black market use for bodybuilding purposes, with this, in some countries such as the Netherlands, being an illicit use.[7][9]

CJC-1295 is a tetrasubstituted 30-amino acid peptide hormone, primarily functioning as a growth hormone releasing hormone (GHRH) analog. It was invented by ConjuChem, a Canadian biotechnology company. One of the advantages of CJC-1295 over traditional GHRH or rHGH is its ability to bioconjugate with serum albumin, thus increasing its half-life and therapeutic window. It accomplishes this by using protecting groups around the amino acids of GHRH typically susceptible to enzymatic degradation. ConjuChem initiated clinical trials for CJC-1295 during the mid-2000s. The objective of the drug was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous HGH are presumed to increase lipolysis (fat loss). The trial was ultimately successful for most research subjects.

AGRICON WILL DENY ANY ORDER IF WE FEEL IT WILL NOT BE USED IN CONDITION OF OUR DISCLAIMER WHICH IS AGREED UPON BEFORE PURCHASE

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “CJC 1295 W / DAC 2mg / 2 ml”

Your email address will not be published. Required fields are marked *